Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 2
1967 1
1968 1
1972 1
1975 1
1976 1
1977 4
1978 3
1979 2
1980 4
1981 3
1982 1
1983 2
1984 9
1985 11
1986 11
1987 10
1988 20
1989 17
1990 21
1991 20
1992 16
1993 24
1994 25
1995 25
1996 19
1997 31
1998 47
1999 43
2000 44
2001 69
2002 65
2003 54
2004 62
2005 85
2006 88
2007 84
2008 74
2009 67
2010 59
2011 65
2012 64
2013 66
2014 64
2015 69
2016 59
2017 57
2018 54
2019 52
2020 55
2021 62
2022 58
2023 62
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

1,766 results

Results by year

Filters applied: . Clear all
Page 1
Drugs for menopausal symptoms.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Aug 10;62(1604):124-128. Med Lett Drugs Ther. 2020. PMID: 32960867 Corrected and republished. Review. No abstract available.
TENS plus Oxybutynin bei Urgeinkontinenz im Kindesalter.
[No authors listed] [No authors listed] Aktuelle Urol. 2018 Dec;49(6):462-463. doi: 10.1055/s-0044-100019. Epub 2018 Dec 6. Aktuelle Urol. 2018. PMID: 30522149 German. No abstract available.
Drugs for overactive bladder.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-45. doi: 10.58347/tml.2023.1672a. Med Lett Drugs Ther. 2023. PMID: 36897601 No abstract available.
Ditropan XL (ALZA Corp).
Kamali F. Kamali F. IDrugs. 1999 Apr;2(4):360-5. IDrugs. 1999. PMID: 16158355
In December 1997, Alza filed an NDA for its sustained-release, once-daily oral formulation as Ditropan XL. This was approved in December 1998. US market launch was in early February 1999, and Merrill Lynch predicts 1999 revenues to reach $60 million. Alza intends to expand …
In December 1997, Alza filed an NDA for its sustained-release, once-daily oral formulation as Ditropan XL. This was approved in Decem …
Drugs for menopausal symptoms.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-38. doi: 10.58347/tml.2024.1697a. Med Lett Drugs Ther. 2024. PMID: 38412276 No abstract available.
Drugs for benign prostatic hyperplasia.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2022 May 2;64(1649):65-69. Med Lett Drugs Ther. 2022. PMID: 35471226 No abstract available.
Transdermal oxybutynin.
Baldwin CM, Keating GM. Baldwin CM, et al. Drugs. 2009;69(3):327-37. doi: 10.2165/00003495-200969030-00008. Drugs. 2009. PMID: 19275276 Review.
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ...*Transdermal oxybutynin is generally well tolerated in patients with overactive bladder. ...
*The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. ... …
Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.
Gleason DM, Susset J, White C, Munoz DR, Sand PK. Gleason DM, et al. Urology. 1999 Sep;54(3):420-3. doi: 10.1016/s0090-4295(99)00259-9. Urology. 1999. PMID: 10475346 Clinical Trial.
OBJECTIVES: To evaluate in a 1 6-center, single-treatment study once-daily controlled-release oxybutynin (Ditropan XL) for urinary urge incontinence. METHODS: Two hundred fifty-six participants with urge incontinence or mixed incontinence with a significant urge com …
OBJECTIVES: To evaluate in a 1 6-center, single-treatment study once-daily controlled-release oxybutynin (Ditropan XL) for uri …
Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
Van Arendonk KJ, Knudson MJ, Austin JC, Cooper CS. Van Arendonk KJ, et al. Urology. 2006 Oct;68(4):862-5. doi: 10.1016/j.urology.2006.04.034. Urology. 2006. PMID: 17070368
OBJECTIVES: To examine the response to conversion from regular oxybutynin (Ditropan) to an extended-release form (Ditropan XL) in children with persistent daytime urinary incontinence. ...CONCLUSIONS: The frequency of wetting decreased and the voided volume a …
OBJECTIVES: To examine the response to conversion from regular oxybutynin (Ditropan) to an extended-release form (Ditropan
1,766 results